-
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart B – Quality System Requirements (§820.20 Management responsibility, §820.22 Quality audit, §820.25 Personnel). Form 483 observations and Warning Letters 2017–2025. -
Sale!
Comprehensive laboratory controls enforcement data 2017-2025 -
Comprehensive holding and distribution enforcement data 2017-2025 -
Sale!
Comprehensive packaging and labeling enforcement data 2017-2025 -
Sale!
Comprehensive records and reports enforcement data 2017-2025 -
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart F (Production and Process Controls) with direct links to Form 483 observations and Warning Letters from 2017-2025. -
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart E (Control of Components and Drug Product Containers and Closures) with direct links to Form 483 observations and Warning Letters from 2017-2025. -
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart D (Equipment) with direct links to Form 483 observations and Warning Letters from 2017-2025. -
Sale!
Risk management strategies for combination products that merge drugs, devices, and/or biological products under 21 CFR Parts 211, 820, and 1271.
ComplyFDA delivers authoritative compliance intelligence for pharmaceuticals, medical devices, biologics, and combination products, giving your team the clarity needed to strengthen inspection readiness, evaluate compliance risks, and support continuous quality improvement.
services.
get in touch.
© 2012 - 2026 • Avada is a Website Builder for WordPress and eCommerce • All Rights Reserved • Developed by ThemeFusion
